BNOAT Oncology, Inc. has evaluated nitrosylcobalamin (NO-Cbl) as an anti cancer drug and has published the following scientific studies:
BNOAT Oncology, Inc has achieved several important milestones required for the FDA approval of nitrosylcobalamin including:
NOTE: NO-Cbl is not approved by the FDA and is not available for human or animal use
dedicated to the research and development of Nitric oxide
IN THE NEWS
Congratulations to Emily Cronin for presenting at the 2019 American Chemical Society National Meeting and Exposition. Emily is a senior honors student at Walsh University and participated in the Entrepreneurship in the Sciences Program and was one of the first Walsh University Avengers Against Cancer student interns.
Emily’s project involved the synthesis of a novel agent with anticancer properties. The compound was synthesized using BNOAT Oncology's proprietary nitric oxide-synthesis platform. The compound was identified using a high throughput anticancer drug screen as adapted from the National Cancer Institute's Developmental Therapeutics Program. The research was funded by the National Science Foundation, BNOAT Oncology, Inc. and the Walsh University Honors Program.
BNOAT Oncology, Inc. evaluates the use of nitric oxide to kill bacteria while promoting entrepreneurship in research and job-readiness for Walsh University honors students; see page 7 of the PDF per the link below.
Dr. Annette Sysel, Vice President and Chief Veterinary Officer of BNOAT Oncology,was awarded the 2015 American Hero Veterinarian Award at the American Humane Association Annual Hero Awards!
Watch as Dr. Sysel receives her award:
Congratulations to Dr. Sysel for her continued efforts in the fight against cancer.
Dr. Sysel was selected and presented ground-breaking cancer research at the 2015 American Association for Cancer Research (AACR) Meeting on Sunday, April 19th at 1:00 pm. Refer to AACR site for more details:
BNOAT Oncology presented to the 2014 Bio Investor Forum on October 7th at the Palace Hotel in San Francisco.
Dr. Bauer and Dr. Dunphy attend the Official Dedication of the Timken Foundation of Canton Innovation Corridor home to the REDIzone (Research, Entrepreneurship, Discovery, and Innovation Zone) in partnership with BNOAT Oncology, Inc.
From left to right: Dr. Dunphy, Mr. Jack Timken, Dr. Bauer
Dr. Annette M. Sysel, Vice President of BNOAT Oncology, Inc. presented to the Business Forum at the 2014 BIO International Conference on: Wednesday, June 25th at the San Diego Convention Center.
UARF licenses the exclusive rights to US 5,936,082 to BNOAT Oncology, Inc and is housed on the Akron Innovation Campus of the University of Akron.
United States Patent 5,936,082 issues to the University of Akron Research Foundation (UARF).